Decellularized Human Placental Extracellular Matrix Tissue for Rotator Cuff Repair Augmentation
Part of paid clinical trials in New York, New York.
- Sponsor
- Columbia University
- Study ID
- NCT07027735
- Status
- Recruiting
Conditions
- Rotator Cuff Tear
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Rotator Cuff Repair with Allograft Patch — OTHERRotator cuff repairs will be augmented with use of a decellularized human placental allograft patch
- Rotator Cuff Repair with No Augmentation — OTHERStandard rotator cuff repair with no augmentation
Study Details
The rotator cuff is a set of muscles and tendons that help move the shoulder. Tears in the rotator cuff are common, particularly as people age. Consequently, rotator cuff repair surgeries are common, as well. Despite the frequency with which rotator cuff repairs are performed, there remains a high rate of postoperative failure to heal. In such situations, there is a lack of connective tissue establishment between the rotator cuff tendon and the bone. One strategy to attempt to improve healing of the rotator cuff tendon back to the bone is via the use of extracellular matrix allograft. This treatment is composed of tissue from other humans, which is stripped of its cells so that just the scaffolding around the cells remains. This decellularized scaffolding can be placed at the rotator cuff healing site in an attempt to augment healing. Both animal studies and human studies have shown promise with this approach. Of those patients enrolling in the study, 50% will be assigned at random to receive a standard rotator cuff repair AND allograft treatment, while 50% will be assigned at random to receive standard rotator cuff repair WITHOUT allograft treatment. All patients enrolled in the study will also obtain an MRI at one year following surgery in order to assess tendon healing. Of note, one-year postoperative MRIs are not standard following rotator cuff repair - only those enrolled in the study will receive this MRI. There will be no financial consequence of receiving this MRI.
Key Dates
- Start date
- Aug 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Jul 1, 2027
- Completion
- Jul 1, 2027
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment ArmStandard Rotator Cuff Repair + Receives Allograft Treatment
- Other: Control ArmStandard Rotator Cuff Repair + NO Allograft Treatment
Primary Outcome Measure
Retear Rate [ Time Frame: 1 year ]
Central Contacts
- Andrew J Luzzi, MD18604595700
- Dawn Vega
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NewYorkPresbyterian Hospital @ Columbia | New York | New York | 10032-3702 | William Levine, MD (PRINCIPAL_INVESTIGATOR) Charles Jobin, MD (SUB_INVESTIGATOR) Michael Knudsen, MD (SUB_INVESTIGATOR) |
Find similar trials in New York, NY
Related Studies
- FiberLocker® System Augmentation of Rotator Cuff RepairsRecruiting · ZuriMED Technologies Inc. · Chicago, Illinois